SAN DIEGO (AP) _ Regulus Therapeutics Inc. (RGLS) on Wednesday reported a loss of $14.4 million in its fourth quarter.
The San Diego-based company said it had a loss of 14 cents per share.
The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 17 cents per share.
The biopharmaceutical company posted revenue of $18,000 in the period.
For the year, the company reported that its loss narrowed to $71.9 million, or 96 cents per share. Revenue was reported as $72,000.
In the final minutes of trading on Wednesday, the company's shares hit $1.26. A year ago, they were trading at $1.15.